Published in Curr Oncol Rep on January 01, 2008
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA (2008) 4.48
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med (2008) 3.32
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med (2009) 2.70
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract (2010) 2.59
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol (2010) 2.46
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol (2009) 2.26
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw (2009) 1.73
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol (2011) 1.69
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol (2007) 1.59
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer (2012) 1.52
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol (2006) 1.48
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol (2010) 1.44
Invasive breast cancer. J Natl Compr Canc Netw (2011) 1.43
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer. Oncology (Williston Park) (2007) 1.39
Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess (Full Rep) (2007) 1.35
Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol (2013) 1.32
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res (2004) 1.31
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. Oncologist (2013) 1.29
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.23
Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI. Breast Cancer Res Treat (2007) 1.21
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res (2014) 1.19
Implementing a breast cancer registry and treatment plan/summary program in clinical practice: a pilot program. Cancer (2012) 1.17
Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci (2010) 1.17
Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. Support Care Cancer (2007) 1.14
Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice. Psychooncology (2012) 1.14
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst (2012) 1.13
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw (2013) 1.11
Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat (2011) 1.10
Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care (2010) 1.08
Clinical Practice Guidelines in Oncology: Translating Evidence Into Practice (and back). J Oncol Pract (2005) 1.07
Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res (2008) 0.99
Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol (2010) 0.98
Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res (2010) 0.97
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat (2011) 0.97
The role of informatics in promoting patient-centered care. Cancer J (2011) 0.96
The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol (2012) 0.95
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. J Clin Pharmacol (2011) 0.95
Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) (2008) 0.95
Quality of end-of-life care for patients with advanced cancer in an academic medical center. J Palliat Med (2011) 0.94
Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol Cancer Res Treat (2004) 0.92
Invasive breast cancer. J Natl Compr Canc Netw (2007) 0.92
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) (2011) 0.90
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol (2009) 0.90
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer (2010) 0.90
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res (2004) 0.89
Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab. Stem Cells Transl Med (2012) 0.89
Concordance of cancer patients' function, symptoms, and supportive care needs. Qual Life Res (2009) 0.89
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res (2003) 0.88
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat (2011) 0.87
Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther (2011) 0.86
Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf (2002) 0.86
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat (2011) 0.86
Breast cancer. J Natl Compr Canc Netw (2005) 0.85
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst (2012) 0.84
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol (2009) 0.84
It's who you know: patient-sharing, quality, and costs of cancer survivorship care. J Cancer Surviv (2014) 0.83
With maturity comes confidence: EBCTCG tamoxifen update. Lancet (2011) 0.81
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat (2013) 0.81
Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clin Breast Cancer (2007) 0.81
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clin Cancer Res (2005) 0.81
Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease. Clin Breast Cancer (2012) 0.80
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer (2010) 0.80
Estrogen receptor: a never ending story? J Clin Oncol (2011) 0.79
Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so. J Natl Cancer Inst (2002) 0.78
A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. J Pharm Biomed Anal (2003) 0.78
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat (2014) 0.78
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.78
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat (2015) 0.78
Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Rev Anticancer Ther (2007) 0.78
Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw (2010) 0.78
A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. Biomed Chromatogr (2004) 0.78
Evaluating information prescriptions in two clinical environments. J Med Libr Assoc (2011) 0.78
Reply to G. Sauter et al. J Clin Oncol (2009) 0.77
Detection of circulating tumor cells in the cerebrospinal fluid: a new frontier. Cell Cycle (2012) 0.77
Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials. Breast (2013) 0.77